Integra LifeSciences Holdings Corporation (IART) return on equity (ROE)

Return on equity · fiscal 2025
-49.5%

Integra LifeSciences Holdings Corporation (IART) earned a return on equity of -49.5% in fiscal 2025 (the year ended December 31, 2025). That is 49.0 percentage points lower than the -0.4% of fiscal 2024. Figures as of 18 Nov 2026, 12:28 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-49.5%
Change on fiscal 2024
−49.0 pts
Highest on record
13.1%fiscal 2010
Lowest on record
-49.5%fiscal 2025
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Integra LifeSciences Holdings Corporation return on equity (ROE), in more detail

Across the 18 fiscal years on record (2008–2025), the highest was 13.1% in fiscal 2010 and the lowest -49.5% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 17 earlier fiscal years on record, whose median is 6.7%.

History · 18 fiscal years

Return on equity by fiscal year

Integra LifeSciences Holdings Corporation return on equity (ROE), year by year

Integra LifeSciences Holdings Corporation (IART) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-49.5% 49.0 pts down
2024-0.4% 4.7 pts down
20234.3% 5.7 pts down
202210.0% 0.0 pts
202110.0% 1.2 pts up
20208.8% 5.3 pts up
20193.5% 0.9 pts down
20184.4% 2.3 pts down
20176.7% 2.2 pts down
20168.9% 9.3 pts up
2015-0.5% 5.3 pts down
20144.8% 8.0 pts up
2013-3.2% 11.1 pts down
20128.0% 2.3 pts up
20115.7% 7.5 pts down
201013.1% 1.7 pts up
200911.5% 4.0 pts up
20087.4%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on IART

Integra LifeSciences Holdings Corporation, figure by figure

Integra LifeSciences Holdings Corporation (IART) overview: price, valuation and scorecard

Integra LifeSciences Holdings Corporation return on equity (ROE): questions and answers

What is Integra LifeSciences Holdings Corporation's return on equity?

Integra LifeSciences Holdings Corporation (IART) earned a return on equity of -49.5% in fiscal 2025 (the year ended December 31, 2025). That is 49.0 percentage points lower than the -0.4% of fiscal 2024.

Is Integra LifeSciences Holdings Corporation's return on equity high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 17 earlier fiscal years on record, whose median is 6.7%.

What are the highest and lowest return on equity figures on record for Integra LifeSciences Holdings Corporation?

Across the 18 fiscal years on record (2008–2025), the highest was 13.1% in fiscal 2010 and the lowest -49.5% in fiscal 2025.

How is Integra LifeSciences Holdings Corporation's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative. For Integra LifeSciences Holdings Corporation it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Integra LifeSciences Holdings Corporation (IART) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/IART/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.